How is cetrorelix different from a GnRH agonist like leuprolide?

Cetrorelix is a receptor antagonist, so it suppresses LH and FSH immediately without the initial hormonal flare that agonists cause before down-regulation.

Does cetrorelix cause a testosterone or estrogen flare?

No. Because it blocks the receptor directly rather than first stimulating it, there is no initial surge in gonadotropins or sex steroids.

Is cetrorelix a performance or bodybuilding drug?

No. It is a prescription reproductive-medicine drug; there is no legitimate performance-enhancement use, and it should only be used under a clinician's supervision.

What are the common side effects?

In ART use, side effects are usually mild injection-site reactions; more serious risks such as ovarian hyperstimulation relate to the stimulation cycle overall and require medical monitoring.

EMA-approvedaka Cetrotide

Cetrorelix — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Cetrorelix (also known as Cetrotide) is a peptide catalogued under Sexual Health (GnRH antagonist). It is described as: GnRH receptor antagonist. Documented context: Assisted reproduction. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Cetrorelix?

Cetrorelix (marketed as Cetrotide) is a synthetic decapeptide gonadotropin-releasing hormone (GnRH) receptor antagonist, approved by the US FDA and the EMA to prevent premature luteinizing hormone (LH) surges in women undergoing controlled ovarian stimulation for assisted reproduction (IVF/ICSI).

Its evidence base is human and robust, including multiple randomized controlled trials in assisted reproduction and dose-ranging trials in benign prostatic hyperplasia.

It is a prescription drug used only under medical supervision, not a research or lifestyle supplement.

How does Cetrorelix work?

Cetrorelix competitively blocks pituitary GnRH receptors, producing immediate, dose-dependent suppression of LH and FSH secretion.

Because it is an antagonist rather than an agonist, it causes no initial gonadotropin or steroid flare, so suppression begins within hours without the transient surge seen when GnRH agonists are started.

What does the research say about Cetrorelix?

Cetrorelix prevents premature LH surges during controlled ovarian stimulation, with efficacy comparable to the antagonist ganirelix in a head-to-head randomized trial. ^[1]
In a multicenter randomized trial, cetrorelix effectively prevented premature LH surges during letrozole-plus-gonadotropin stimulation. ^[2]
Cetrorelix significantly reduced premature luteinization rates in gonadotropin intrauterine-insemination cycles in a randomized controlled trial. ^[3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies — Wilcox J et al., Fertility and Sterility 2005. (Multicenter randomized controlled trial (head-to-head vs ganirelix))
[2] Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins: a randomized trial — Lee TH et al., Fertility and Sterility 2008. (Multicenter randomized controlled trial)
[3] Cetrorelix lowers premature luteinization rate in gonadotropin ovulation induction-intrauterine insemination cycles: a randomized-controlled clinical trial — Steward RG et al., Fertility and Sterility 2011. (Randomized controlled trial)
[4] Safety and efficacy of mixing cetrorelix with follitropin alfa: a randomized study — Lin YH et al., Fertility and Sterility 2010. (Randomized controlled trial)
[5] Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia — Debruyne F et al., Urology 2010. (Multicenter randomized controlled trial)
[6] Cetrorelix in reproductive medicine — Findeklee S et al., F&S Reports 2023. (Narrative review)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

For context only: in IVF it is given subcutaneously during the mid-to-late follicular phase, either as repeated low daily doses (multiple-dose protocol) or as a single higher dose (single-dose protocol), timed against follicle monitoring.

Dosing, timing, and eligibility are determined by a fertility specialist within a supervised cycle and are outside the scope of self-administration.

Side effects & safety profile

In assisted-reproduction use, cetrorelix is generally well tolerated; the most common effects are mild, transient injection-site reactions (redness, itching, swelling) and effects related to ovarian stimulation itself.

As with any drug acting on the reproductive axis, it must be used only within a monitored clinical protocol; ovarian hyperstimulation syndrome remains a risk of the underlying stimulation cycle rather than the antagonist itself.

Hypersensitivity reactions have been reported rarely.

Stacking & combinations

In clinical use it is co-administered only with prescribed gonadotropins (FSH/hMG) inside a physician-supervised stimulation protocol; it is not intended for non-medical stacking with other agents.

Finding Cetrorelix vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is approved (FDA and EMA) to prevent premature LH surges in women undergoing controlled ovarian stimulation for assisted reproduction such as IVF or ICSI.

References

[1] Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies — Wilcox J et al., Fertility and Sterility 2005. PMID: 16009165. View sourceStudy: Multicenter randomized controlled trial (head-to-head vs ganirelix)Cetrorelix and ganirelix gave comparable LH-surge prevention and clinical outcomes in a flexible ART protocol.
[2] Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins: a randomized trial — Lee TH et al., Fertility and Sterility 2008. PMID: 18054932. View sourceStudy: Multicenter randomized controlled trialCetrorelix effectively prevented premature LH surges during letrozole/gonadotropin stimulation.
[3] Cetrorelix lowers premature luteinization rate in gonadotropin ovulation induction-intrauterine insemination cycles: a randomized-controlled clinical trial — Steward RG et al., Fertility and Sterility 2011. PMID: 20810107. View sourceStudy: Randomized controlled trialAdding cetrorelix reduced premature luteinization in gonadotropin IUI cycles.
[4] Safety and efficacy of mixing cetrorelix with follitropin alfa: a randomized study — Lin YH et al., Fertility and Sterility 2010. PMID: 19339001. View sourceStudy: Randomized controlled trialMixing cetrorelix with follitropin alfa in one injection was safe and did not compromise efficacy.
[5] Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia — Debruyne F et al., Urology 2010. PMID: 20932411. View sourceStudy: Multicenter randomized controlled trialCetrorelix pamoate improved lower-urinary-tract symptoms in men with BPH, illustrating GnRH-antagonist activity beyond reproduction.
[6] Cetrorelix in reproductive medicine — Findeklee S et al., F&S Reports 2023. PMID: 37223762. View sourceStudy: Narrative reviewReviews the pharmacology and clinical role of cetrorelix in preventing premature LH surges during ART.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.